1. Diagnosis of Burkitt lymphoma/leukemia, heterozygous or double-hit leukemia, or chronic myeloid leukemia in blast crisis.
2. Presence of ≥5% blasts in the bone marrow or peripheral blood, or evidence of extramedullary leukemia before screening or preconditioning.
3. Prior treatment with CAR-T cell therapy or hematopoietic stem cell transplantation (HSCT) before screening or preconditioning.
4. Genetic syndromes associated with bone marrow failure, including Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other known bone marrow failure syndromes.
5. Presence of any of the following conditions:
1. Positive for HBsAg and/or HBeAg.
2. Positive for HBe-Ab and/or HBc-Ab with HBV-DNA levels above the detectable threshold.
3. Positive for HCV-Ab.
4. Positive for TP-Ab.
5. EBV-DNA or CMV-DNA levels above the detectable threshold.
6. Positive for HIV antibodies.
6. Diagnosis of other malignancies within the past 5 years, unless the tumor was curatively treated, with a follow-up period exceeding 5 years, and a low risk of recurrence as assessed by the investigator.
7. Presence of any of the following cardiac conditions:
1. Left ventricular ejection fraction (LVEF) ≤45%.
2. Congestive heart failure classified as NYHA class III or IV.
3. Severe arrhythmias requiring treatment or clinically significant conduction abnormalities on ECG, including QTc ≥480 ms (QTcB = QT/RR^1/2).
4. Uncontrolled hypertension (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥100 mmHg) or pulmonary hypertension despite standard treatment.
5. Unstable angina.
6. Myocardial infarction or coronary artery bypass/stent surgery within the past 6 months.
7. Clinically significant valvular disease.
8. Other cardiac conditions deemed unsuitable for study enrollment by the investigator.
8. History of epilepsy, ischemic or hemorrhagic stroke, cerebellar disease, or other active central nervous system disorders.
9. Clinically significant pleural effusion at the time of screening.
10. History of deep vein thrombosis or pulmonary embolism within the past 6 months.
11. Known hypersensitivity to any components of the investigational products used in the trial.
12. Receipt of live vaccines within 6 weeks prior to screening.
13. Presence of active infections at the time of screening.
14. An expected survival of less than 3 months.
15. Participation in other interventional clinical studies involving investigational drugs:
1. For investigational drugs not yet approved, the last dose administered less than 3 months before cell infusion.
2. For approved drugs, the last dose administered less than 5 half-lives before cell infusion.
16. Any other conditions deemed unsuitable for study participation by the investigator.